aclofen (4-amino-3-[4-chlorophenyl]-butanoic acid) is a GABA B agonist used in the treatment of spasticity and dystonia. The mode of action in spasticity is thought to be at Rexed laminae I and II in the superficial layers of the spinal cord where baclofen inhibits the release of glutamate; the mode of action in dystonia is not known but thought to be at the cortical level. Baclofen was discovered in the 1970s, and it received FDA approval for oral use in 1977 and for intrathecal use in 1997. It became apparent that the levels of baclofen in the CSF, when given intrathecally, were much higher than when given orally (380 ng/ ml rather than 12-95 ng/ml 1 ) and it was clinically more effective. Plasma levels after intrathecal administration of baclofen are extremely low, thereby reducing side effects. To establish an intrathecal delivery system intrathecal pumps were adapted from pumps used to infuse opioids in cancer patients and the first intrathecal baclofen pumps were implanted in 1985.
B aclofen (4-amino-3-[4-chlorophenyl]-butanoic acid)
is a GABA B agonist used in the treatment of spasticity and dystonia. The mode of action in spasticity is thought to be at Rexed laminae I and II in the superficial layers of the spinal cord where baclofen inhibits the release of glutamate; the mode of action in dystonia is not known but thought to be at the cortical level. Baclofen was discovered in the 1970s, and it received FDA approval for oral use in 1977 and for intrathecal use in 1997. It became apparent that the levels of baclofen in the CSF, when given intrathecally, were much higher than when given orally (380 ng/ ml rather than 12-95 ng/ml 1 ) and it was clinically more effective. Plasma levels after intrathecal administration of baclofen are extremely low, thereby reducing side effects. To establish an intrathecal delivery system intrathecal pumps were adapted from pumps used to infuse opioids in cancer patients and the first intrathecal baclofen pumps were implanted in 1985.
The range of management options for spasticity includes oral medications, treatment for focal spasticity such as botulinum toxin injections, or selective peripheral neurotomy with or without serial casting and selective dorsal rhizotomy for more generalized spasticity. The physician and family should give careful consideration to selecting the most appropriate treatment. To avoid disappointment and unrealistic expectations, it is important to counsel patients and families appropriately and have agreed-upon goals for therapy. The aim of intrathecal baclofen is not only the reduction of spasticity but facilitation of care, reduction of pain and therefore improvement of sleep, slowing or prevention of musculoskeletal contractures, and improvement of function.
to say that there is a well-recognized link between rapid growth prior to skeletal maturation and a high risk of developing scoliosis. 5 Treatment plans depend on the ability to assess growth potential and therefore the likelihood of curve development or progression. In girls, skeletal maturity can be predicted by using a combination of age at menarche, Risser signs, and peak height velocity. 3 There is a 90% probability of cessation of growth at peak height velocity plus 3.6 years. 3 The natural history of scoliosis development in patients with cerebral palsy is an important consideration when scrutinizing the effect of intrathecal baclofen. Saito et al. 6 analyzed data obtained in 79 children with spastic cerebral palsy, 54 (68%) of whom had scoliosis. The authors found that most scoliosis develops in individuals before the age of 10 years, advances most rapidly soon after onset, and progresses into adulthood. Significantly, patients in whom a curve of greater than 40° had developed before the age of 15 years were more likely to experience progression to severe scoliosis. Patients with a curve of less than 40° at the age of 15 years had more slowly progressive scoliosis. Thometz and Simon 12 also confirmed that the rate of scoliosis progression varied according to the curve at the time of skeletal maturity. The rate of progression was 0.8° per year in patients whose curves were greater than 50° at the time of skeletal maturity and 1.4° in patients whose curves were more than 50° at the time of skeletal maturity. The rate of progression of scoliosis in adult patients with cerebral palsy has been shown to be between 3.0 and 4.4° per annum. 4 Although the use of intrathecal baclofen has been very promising in the management of spasticity and dystonia, there has been considerable concern regarding the acceleration in the scoliosis development in the population. In an attempt to add our experience to the ever-increasing body of literature on this subject we reviewed the data obtained in our group of patients in whom intrathecal baclofen pumps had been implanted.
Methods
Case notes and radiological studies were reviewed on 2 different sites: the acute pediatric hospital where the surgery and initial follow-up are performed and the rehabilitation center where the Spasticity Clinic is held. Information was gathered by 3 investigators and tabulated on a data collection tool. Cobb angles were measured on pre-and postoperative 3-ft spine radiographs, coronal chest radiographs (standing when possible), and on abdominal radiographs (the Picture Archiving and Communications Systems) by a radiologist or neurosurgeon. Mean Cobb angle progression per year was calculated. All other causes of progressive scoliosis were excluded.
Results
Forty-two cases were investigated for feasibility of baclofen pump insertion. All 42 patients underwent Stage I screening, which involves intrathecal injection of baclofen either via a lumbar drain or lumbar puncture. Four patients were excluded from the study following Stage I for the following reasons: nausea and vomiting experienced during Stage I, with the family opting out before Stage II; failed attempt at Stage I, not repeated; Stage II not completed; and an expected death unrelated to pump insertion 16 days following implantation. Of the remaining 38 patients, 32 had adequate pre-and postoperative imaging studies and so were included in the study. Their diagnoses were as follows: spastic cerebral palsy in 16, dystonic cerebral palsy in 7, hypoxic injury/head injury/ cerebrovascular accident in 4, and other (dystonia secondary to metabolic disorders and spasticity secondary to adrenoleukodystrophy) in 5 patients. Patients' mean age at pump insertion was 10.6 years (range 4-17 years), and the male/female ratio was 25:13. The mean follow-up period was 31 months (range 1-118 months).
The pump was removed in 4 patients for various reasons (Table 1) including concern over rapid development of scoliosis. In cases in which the pump was removed, scoliosis development was followed until the date of pump removal in all except for 1 of the group. In this patient, Case 1, who underwent follow-up imaging after the pump was removed, studies revealed a slowing in the scoliosis curve progression. The patient was 15 years of age at the time of pump insertion and had no evidence of scoliosis preoperatively. When the pump was removed 32 months later, the Cobb angle was 53°, a rate of progression of 1.66° per month. The patients last follow-up was 31 months following pump removal at which time the Cobb angle was 75°, a rate of progression of 0.75° since pump removal.
The patient characteristics and Cobb angle progression rates are shown in Table 2 and the mean annual Cobb angle progression for each of the 4 subgroups is shown in Table  3 . The graph in Fig. 1 shows the development of scoliosis plotted as age in months against Cobb angle. The radiographs in Fig. 2 demonstrate the progression of scoliosis at 4 intervals after pump implantation. Scoliosis did not develop in 7 patients. In 4 patients (Cases 7, 24, 29, and 31) we noted an inflection in the progression rate that was spontaneous rather than related to pump removal. Analysis of curve progression before and after growth spurt showed a greater rate of curve progression in patients with pumps inserted before the age of 15 years (Table 4) .
Discussion
There is a small but increasing body of evidence in 6 and baclofen pumps are often inserted around the time of the adolescent growth spurt (age 10-15 years). 5 This makes the differentiation of the effect of intrathecal baclofen from the natural history of cerebral palsy difficult. The ideal method of teasing out whether intrathecal baclofen increases the rate of scoliosis development would be with a control group. The patients would need to be matched according to age, demographics, degree of spasticity, degree of dystonia, medication, previous orthopedic procedures, and so on. It is unlikely that such a group exists, as our patients are a very severely affected group in whom previous treatment methods have failed and who are in great discomfort. Such families would be unlikely to refuse a baclofen pump should it be offered to them. Our group also contains a number of patients with rare disorders for which matched controls would be hard to find. Ginsburg and Lauder 2 have reported on 19 patients with spastic quadriplegia, who were between 1 and 19 years of age at pump insertion. The scoliosis development rate increased from 1.825° per year before pump insertion to 10.95° after pump insertion. This incidence is considerably higher than the 3-4.4° per year progression quoted in the literature for adult patients with cerebral palsy and no pumps and the 0.8-1.4° per year progression in young adults (15-35 years of age); however, in both of these groups the growth spurt has already completed. Sansone at al. 7 have discussed 4 cases of patients between 4 and 19 years of age, all with spastic quadriplegia, and all of whom developed rapidly worsening scoliosis resulting in spinal fusion. A 4-year-old patient and a 19-year-old patient were the only truly notable cases because the patients' ages are considered outside of the growth spurt period.
Segal et al. 9 published a report of 5 patients who underwent spinal fusion following insertion of intrathecal baclofen pumps. The patients were between ages 12 and 20 years at the time of pump insertion, and the diagnosis was spastic quadriplegia cerebral palsy in all 5. The curve progression rate increased from a mean of 7.5° per year to a mean of 38.05° per year. The same authors also discussed reports that patients with spasticity treated with selective dorsal rhizotomy also develop scoliosis postoperatively and that it has been postulated that this is a result of decreased muscle tone following the rhizotomy. A notable report of development of scoliosis following the insertion of an opioid intrathecal pump for the treatment of back pain raises the possibility that it is not necessarily only intrathecal baclofen that may accelerate the development of scoliosis. 8 Certainly attention should be paid to any sign of development of scoliosis de novo or acceleration of preexisting scoliosis when considering any type of intrathecal neuromodulation.
Two publications in the literature do not support the claims that intrathecal baclofen pumps accelerate the development of scoliosis. Senaran et al. 10 reported on 107 patients, between the ages of 5 and 18 years, with spastic cerebral palsy who were treated with intrathecal baclofen. Twenty-six of these patients developed scoliosis. Twentyfive patients were matched with controls by age, sex, and a gross motor function classification system. The curve progression rate was 16.3° per year in the pump group and 16.1° per year in the control group. More recently Shilt at al.
11 published a study of 50 patients with spastic cerebral palsy matched with 50 controls on the basis of age (3-18 years), sex, topographical involvement, and initial Cobb angle. The mean annual progression in Cobb angle was 6.6° in the pump-treated group and 5.0° in the control group. However, the range of annual curve progression was −4.9 to 63.7° in the pump group and −4.1 to 27.7° in the control group, and there may have been intergroup differences not revealed by use of a t-test, which assumes normal distribution.
The mode of action of baclofen in the possible acceleration in the scoliosis development is not clearly understood. However, it has been proposed that baclofeninduced hypotonia increases the instability of any, even mild, preexisting spinal deformity. Thus deprived from its muscular control, the collapse of the spine accelerates the progression toward a kyphoscoliotic deformity.
Our results show a wide range of outcomes, from no scoliosis development to progression of preexisting scoliosis and new scoliosis development. This range of results was seen across all our diagnostic groups. The mean annual progression in Cobb angle in the entire group was 18.43° (range 0-67.68°, median 12.13°), which is higher than in previously reported case series. 2, 10, 11 The mean annual Cobb angle progression was similar in all 4 subgroups (range 15.54-20.27°) and so prediction of patients most likely to develop scoliosis on the basis of the underlying diagnosis could not be made in this group. This study does have a number of weaknesses, not least the lack of a control group, but also failure to collect data concerning the age of menarche, Risser signs, and peak height velocity in female patients. Despite this we believe that the rate of scoliosis development in some of our cases is unacceptably high compared with data available in the literature.
Conclusions
Our data lend further support that intrathecal baclofen may increase the rate of scoliosis development in some patients in whom a baclofen pump has been implanted. This issue is important because scoliosis can lead to a number of adverse outcomes including those that intrathecal baclofen therapy is meant to address-ease of activities of daily living, seating, pain, and so on. Severe scoliosis, as seen in some patients, can lead to respiratory infections, failure, and to death. The effect of intrathecal baclofen on scoliosis could perhaps be best addressed through a prospective case-control study in large number of patients, a study we would recommend. In the meantime, we suggest that patients with baclofen pumps be monitored clinically and, if appropriately, radiologically for the development of scoliosis.
